1. Home
  2. PCN vs PHAR Comparison

PCN vs PHAR Comparison

Compare PCN & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pimco Corporate & Income Strategy Fund

PCN

Pimco Corporate & Income Strategy Fund

HOLD

Current Price

$11.71

Market Cap

880.2M

Sector

Finance

ML Signal

HOLD

Logo Pharming Group N.V.

PHAR

Pharming Group N.V.

HOLD

Current Price

$11.11

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PCN
PHAR
Founded
N/A
1988
Country
United States
Netherlands
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
880.2M
1.0B
IPO Year
2001
2020

Fundamental Metrics

Financial Performance
Metric
PCN
PHAR
Price
$11.71
$11.11
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$38.33
AVG Volume (30 Days)
341.2K
21.9K
Earning Date
01-01-0001
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$10.04
Revenue Next Year
N/A
$2.51
P/E Ratio
N/A
$3,041.22
Revenue Growth
N/A
N/A
52 Week Low
$11.40
$9.62
52 Week High
$13.49
$21.34

Technical Indicators

Market Signals
Indicator
PCN
PHAR
Relative Strength Index (RSI) 47.48 40.99
Support Level $11.56 $9.62
Resistance Level $11.83 $13.51
Average True Range (ATR) 0.08 0.49
MACD -0.00 0.02
Stochastic Oscillator 41.91 5.27

Price Performance

Historical Comparison
PCN
PHAR

About PCN Pimco Corporate & Income Strategy Fund

PIMCO Corporate & Income Strategy Fund is a closed-end management investment company. Its objective is to seek high current income with capital appreciation as a secondary objective. It invests in corporate bonds and notes, non-agency mortgage-backed securities, asset-backed securities, short-term instruments, and others.

About PHAR Pharming Group N.V.

Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.

Share on Social Networks: